Top Markets
#1 Akedo Akedo +64.92%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +48.99%
#4 Velvet Velvet +39.58%
#5 Black Phoenix Black Phoenix +34.15%
#6 Cross Cross +32.99%
#7 Cap Cap +29.09%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.02%
#9 DoubleZero DoubleZero +13.10%
#10 Humanity Humanity +11.79%
Coin of the day
Akedo Akedo
Settings
Language
ENGLISH
Currency
USD
Theme
Lipidor AB (publ) Lipidor AB (publ)

Lipidor AB (publ)

LIPI
Rank in Stocks #39100
Lipidor AB (publ), a Swedish pharmaceutical company founded in Danderyd in... Lipidor AB (publ), a Swedish pharmaceutical company founded in Danderyd in 2009, specializes in developing medicinal products. Its core business centers on creating treatments for various skin conditions, including psoriasis, bacterial skin infections, and atopic dermatitis. The company's product pipeline includes AKP-01, which is currently in Phase III clinical trials for psoriasis, while other formulations like AKP-02 (also for psoriasis) and AKP-03 and AKP-07 (for eczema) are in earlier, preclinical development stages. Beyond its own drug candidates, Lipidor manufactures and supplies active pharmaceutical ingredients (APIs). These APIs are incorporated into products addressing a broad spectrum of therapeutic applications, such as managing psoriasis, microbial infections, inflammation, fungal issues, local pain relief, acne, wound healing, eczema, and migraines. Lipidor also caters to the animal health market, offering a line of spray-on skin care products for dogs, cats, and horses. Additionally, it develops consumer health items designed for purposes like antibacterial action, antiseptic care, moisturizing, disinfection, and treating acne and warts. In a key strategic alliance, Lipidor has partnered with Cannassure Therapeutics Ltd. This collaboration aims to advance topical medicinal cannabis products specifically formulated to alleviate skin inflammations and psoriatic lesions.
Share Price
$0.02243487
Last synced: 2025-06-04
Market Cap
$650.09K
Change (1 day)
0.39%
Change (1 year)
0.00%
Country
SE
Trade Lipidor AB (publ) (LIPI)

Category

Healthcare
Revenue for Lipidor AB (publ) (LIPI)
Revenue in Dec 2024 TTM: $265.61K
According to Lipidor AB (publ) latest financial reports the company's current revenue (TTM) is $265.61K. In 2023 the company made a revenue of $7.73K an increase over the revenue in the year 2022 that was $4.32K. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Lipidor AB (publ) from 2016 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) $265.61K 20,825.07%
2024 $1.27K -83.58%
2023 $7.73K 79.16%
2022 $4.32K -99.75%
2021 $1.70M 2,164.63%
2020 $75.02K 872.70%
2019 $7.71K -71.64%
2018 $27.20K -32.61%
2017 $40.36K 30.11%
2016 $31.02K 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
 $79.67B 29,992,925.40%
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
 $97.93B 36,868,756.95%
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
 $64.39B 24,240,300.94%
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
 $77.52B 29,184,513.78%
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
 $66.40B 24,998,542.91%
US